TeaserWe expect Thermo Fisher Scientific stock to have a profit margin of 17.75%, supported by new cell and gene therapy centers and a $5 billion share buyback program.
- High profit margin of 17.75 % – a sign of economies of scale and pricing power.
- New centers and FDA approval strengthen its position in future fields of medicine.
- TransparentShare rating 5/11 with a buy recommendation – quality, but not without risks.
Thermo Fisher Scientific is a global leader in laboratory and analytical equipment. Thermo Fisher Scientific stock benefits from its broad portfolio, ranging from laboratory instruments and diagnostics to services. The company recently opened its East Coast Advanced Therapies Collaboration Center in Philadelphia. This new center supports startups and biopharmaceutical companies in developing cell and gene therapies and complements the existing Carlsbad location in the US. With this move, Thermo Fisher is targeting one of the most exciting areas of modern medicine, where therapies aim to treat or even cure diseases previously considered incurable.
View the 'Thermo Fisher' review now
Thermo Fisher Scientific strengthens its profile in the diagnostics sector
The US Food and Drug Administration (FDA) has granted approval to the EXENT system for the diagnosis of multiple myeloma. Such specialized solutions are crucial for translating substantial research efforts into tangible products. At the same time, the company is demonstrating its financial strength: A $5 billion share buyback program and a confirmed quarterly dividend underscore that Thermo Fisher is generating sufficient funds for both shareholder returns and growth. This is viewed positively in the TransparentShare rating. In this context, insider sales amounting to millions of dollars are more likely to be seen as part of personal wealth planning than as a fundamental sign of distrust in Thermo Fisher Scientific stock.
TransparentShare rating: The most important metric
In the TransparentShare rating, Thermo Fisher Scientific stock currently achieves 5 out of 11 points – with a "Buy" recommendation. The profit margin of 17.75 percent indicates that Thermo Fisher operates profitably thanks to economies of scale, a strong market position, and a high-quality product mix.
View the 'Thermo Fisher' review now
Regardless of the rating, there are risks such as a very active acquisition strategy with integration costs, high capital requirements in research and development, and the dependence of customers' investment budgets on economic cycles.
Get the complete rating for free!
For investors who are focused on laboratory equipment, diagnostics and future fields such as cell and gene therapy for the long term, the ThermoFisher ScientificStocks can be a building block in your portfolio, especially if you can tolerate fluctuations during periods of weaker investment activity.
You can see in detail how key figures such as margin, share price momentum, and earnings growth expectations contribute to the TransparentShare rating of 5/11 points directly in the app. Use the voucher code TEST21 to secure 21 days of free access to analyze the Thermo Fisher Scientific share key figure by key figure.
